Tannic Acid

Tannic Acid

SCHEMBL13287055

O=C(OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 1.00
▸ MAPK1 P28482 2/20 1.00
▸ TMPRSS2 O15393 1/20 1.00
▸ PDE5A O76074 1/20 1.00
▸ CA1 P00915 1/20 1.00
▸ CA2 P00918 1/20 1.00
▸ HMGCR P04035 1/20 1.00
▸ CYP1A2 P05177 1/20 1.00
▸ LCK P06239 1/20 1.00
▸ FYN P06241 1/20 1.00
▸ HSPD1 P10809 1/20 1.00
▸ CYP2C9 P11712 1/20 1.00
▸ CA6 P23280 1/20 1.00
▸ TBXAS1 P24557 1/20 1.00
▸ MAPK3 P27361 1/20 1.00
▸ HSPE1 P61604 1/20 1.00
▸ MAPK14 Q16539 1/20 1.00
▸ TST Q16762 1/20 1.00
▸ SLCO1B3 Q9NPD5 1/20 1.00
▸ L3MBTL1 Q9Y468 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tannic Acid SCHEMBL409692 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
Tannic Acid SCHEMBL17124527 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
SCHEMBL14339415 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
Tannic Acid SCHEMBL22105299 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
SCHEMBL23630701 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
Tannic Acid SCHEMBL13287221 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
SCHEMBL23630733 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
SCHEMBL23630709 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
Tannic Acid SCHEMBL25066810 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1
Tannic Acid SCHEMBL21865640 1.00 USP2 (1.00) USP2MAPK1TMPRSS2PDE5ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897955-B1 HYDROXYETHYL CELLULOSE MICROCAPSULES INT FLAVORS & FRAGRANCES INC (US) 2024-02-07 — — EP disclosed
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
US-11872236-B2 Pharmacological agents for treating ocular diseases CALASIA PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
US-20230399552-A1 ADHESIVE FOR PELLICLE, PELLICLE FOR PHOTO MASK AND METHOD FOR MANUFACTURING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2023-12-14 — — US disclosed
US-20230399552-A1 ADHESIVE FOR PELLICLE, PELLICLE FOR PHOTO MASK AND METHOD FOR MANUFACTURING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2023-12-14 — — US disclosed
US-20230348734-A1 Conductive Material Dispersion LG ENERGY SOLUTION, LTD. (KR) 2023-11-02 — — US disclosed
US-20230348734-A1 Conductive Material Dispersion LG ENERGY SOLUTION, LTD. (KR) 2023-11-02 — — US disclosed
US-20230320987-A1 LIPID NANOPARTICLES AND LIPOSOMES NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-10-12 — — US disclosed
US-20230320987-A1 LIPID NANOPARTICLES AND LIPOSOMES NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-10-12 — — US disclosed
US-20230218623-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2023-07-13 — — US disclosed
US-20170224876-A1 ARTICLE COATINGS INCLUDING OLIGOMERIZED POLYPHENOL LAYER AND BIOLOGICAL METHODS OF USE SURMODICS, INC. (US) 2017-08-10 — — US disclosed
US-9707316-B2 Crosslinked polymers including one or more antioxidants, methods for making same and methods for selecting antioxidants ZIMMER, INC. (US) 2017-07-18 — — US disclosed
US-9707316-B2 Crosslinked polymers including one or more antioxidants, methods for making same and methods for selecting antioxidants ZIMMER, INC. (US) 2017-07-18 — — US disclosed
US-20160250381-A1 CROSSLINKED POLYMERS INCLUDING ONE OR MORE ANTIOXIDANTS, METHODS FOR MAKING SAME AND METHODS FOR SELECTING ANTIOXIDANTS ZIMMER INC (US) 2016-09-01 — — US disclosed
US-20160250381-A1 CROSSLINKED POLYMERS INCLUDING ONE OR MORE ANTIOXIDANTS, METHODS FOR MAKING SAME AND METHODS FOR SELECTING ANTIOXIDANTS ZIMMER INC (US) 2016-09-01 — — US disclosed
US-9370602-B2 Crosslinked polymers including one or more antioxidants, methods for making same and methods for selecting antioxidants ZIMMER, INC. (US) 2016-06-21 — — US disclosed
US-9370602-B2 Crosslinked polymers including one or more antioxidants, methods for making same and methods for selecting antioxidants ZIMMER, INC. (US) 2016-06-21 — — US disclosed
US-20160151518-A1 RADIOLABELLED MATERIAL THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2016-06-02 — — US disclosed
US-20160151518-A1 RADIOLABELLED MATERIAL THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 2016-06-02 — — US disclosed
WO-2010069845-A1 FOOD COMPOSITION CONTAINING POLYPHENOLS UNILEVER PLC (GB) 2010-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151518-A1 RADIOLABELLED MATERIAL MPI, MKI67, DUT USP2 1133/4885MAPK1 3952/4885TMPRSS2 4626/4885
US-11872236-B2 Pharmacological agents for treating ocular diseases CRYAA, CRYAB, TTR USP2 2086/4885MAPK1 2714/4885TMPRSS2 4238/4885
US-20230320987-A1 LIPID NANOPARTICLES AND LIPOSOMES PHOSPHO1, LIPA, PLIN3 USP2 470/4885MAPK1 1769/4885TMPRSS2 3553/4885
US-20230218623-A1 SALTS OF NEUROCEUTICALS AND USES THEREOF SLC1A2, GABRA6, GABRA2 USP2 4849/4885MAPK1 1642/4885TMPRSS2 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback